Alexion guides cautiously for 2018

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) reported strong 4Q17 earns Thursday, including sales of hematology and autoimmune drug Soliris eculizumab, but its 2018 guidance fell shy

Read the full 240 word article

User Sign In